Instruction for use: Microfollin

Active substance: Ethinylestradiol

ÀÒÕ Code: G03CA01 Ethinylestradiol

Pharmacological groups

Contraceptive agent [Estrogens, gestagens; their homologs and antagonists]

Nosological classification (ICD-10)

L70 Acne

Acne nodulocystica, Acne, Comedone acne, Acne Treatment, Papulous pustular acne, Papulopustulicular acne, Papulo-pustular acne, Acne, Acne Disease, Acne, Acne vulgaris, Nodular-cystic acne, Nodular-cystic acne

N91 Lack of menstruation, meager and rare menstruation

Amenorrhea, Amenorrhea hypogonadotropic, Amenorrhea is prolactin-dependent, Oligomenorrhoea, Shortening of the secretory phase of the menstrual cycle, Menstrual disorders, Menstruation disorders, Prolactin-dependent amenorrhea without galactorrhea

N93 Other abnormal bleeding from the uterus and vagina

Atonic uterine bleeding, Prolonged menstruation, Blood loss during menstruation, Bleeding from the genitourinary system, Bleeding uterine dysfunctional, Bleeding from the genital tract of organic etiology, Uterine bleeding, Menorrhagia with fibroids, Functional uterine bleeding, Abnormal bleeding from the genitals in women

N94.6 Dysmenorrhea Unspecified

Pain during menstruation, Functional disorders of the menstrual cycle, Menstrual cramps, Emmeniopathy, Pain during menstruation, Painful menstrual irregularities, algomenorrhea, algomenoreya, Pain smooth muscle spasm, Pain spasm of smooth muscles (renal and biliary colic, intestinal spasms, dysmenorrhea), Pain spasm of smooth muscles of internal organs (kidney and biliary colic, intestinal spasms, dysmenorrhea), Disalgomenoreya, dysmenorrhea, Dysmenorrhea (essential) (Exfoliative), menstrual disorder, menstruation painful, metrorrhagia, Violation of the menstrual cycle, Menstrual irregularities, Prolaktinzavisimoe menstrual disorders, Prolaktinzavisimoe menstrual dysfunction, Pain spasm of smooth muscles of internal organs, Spasmodic dysmenorrhea, Primary disalgomenoreya

N95.1 menopausal and menopausal status of women

Atrophy of the mucosa of the lower genital tract, caused by estrogen deficiency; Vaginal dryness; Autonomic dysfunction in women; gipoestrogeniya state; Deficiency of estrogen in menopausal women; Degenerative changes of the mucous membrane in the menopause; Natural menopause; an intact uterus; climacteric; Menopause women; Menopause in women; menopausal depression; Climacteric ovarian dysfunction; Menopause; Climacteric neurosis; Menopause; Menopausal symptoms complicated psychovegetative; Climacteric syndrome; Climacteric vegetative disorders; Climacteric psychosomatic disorder; menopausal disorders; Menopausal disorders in women; menopausal condition; Climacteric vascular disorders; Menopause; Menopausal vasomotor symptoms; menopausal period; Lack of estrogen; Feeling the heat; Pathological menopause; perimenopause; menopause; postmenopausal; Premature menopause; premenopauznom period; tides; hot flashes; flushing in the Meno and postmenopausal; Hot flashes / hot flashes in menopause; Heart attack during menopause; Early menopause in women; Disorders of menopause; climacteric syndrome; Vascular complications of menopause; Physiological menopause; Estrogendefitsitnye state; premature Menopause

Composition and form of release

Tablets 1 table.

ethinylestradiol 0.05 mg

auxiliary substances: silicon colloidal dioxide; magnesium stearate; gelatin; talc; corn starch; lactose monohydrate

in a planar cell pack of 10; in the box 1 packing.

Description of dosage form

Tablets of white color are lenticular, odorless, with two dots on one side.

pharmachologic effect

The pharmacological action is estrogenic.

Eliminates the disorders caused by the deficiency of endogenous estrogens, causes proliferation of the endometrium and the epithelium of the vagina, promotes the development of the uterus and secondary female sexual characteristics.

Indication

Amenorrhea, oligomenorrhea, dysmenorrhea, menorrhagia, metrorrhagia, cessation of lactation, acne vulgaris, prostate cancer, climacteric syndrome.

Contraindications

Estrogen-dependent malignant neoplasms of the endometrium and cervix of the uterus, breast cancer (including in men); thrombophlebitis, thromboembolism of the pulmonary artery; impaired cerebral circulation, a violation of liver function.

Side effects

Headache, nausea, vomiting, violation of calcium metabolism, edema, bone marrow hypoplasia.

Dosing and Administration

Inside, adults, the dose is set individually.

In prostate carcinoma: the initial dose is 0.05-0.1 mg 3 times a day, this dose is gradually reduced to a maintenance dose.

For amenorrhea: 1 / 2-1 table. per day for 20 days, after which 5 mg of progesterone is injected in / m for 5 days.

To stop lactation: 1 table. per day for 3 days, in the future - for 1/2 table.

With common acne: 1 / 2-1 table. per day.

storage Conditions

At a temperature of 15-30 ° C.

Keep out of the reach of children.

Shelf life

5 years.

Do not use after the expiry date printed on the package.